Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma

HPB

Volumn 10, Issue 6, 2008, Pages 388-395

  Ng, K M ^a   Niu, R ^a   Yan, T D ^a   Zhao, J ^a   McKay, E ^b   Chu, F C K ^a   Morris, D L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Adjuvant lipiodol I 131; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; IODINATED POPPYSEED OIL I 131; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; FATALITY; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MALE; OVERALL SURVIVAL; PNEUMONIA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE CARE; PROGNOSIS; RADIOFREQUENCY ABLATION; SCORING SYSTEM; SEX DIFFERENCE; SINGLE DRUG DOSE; SURVIVAL RATE; TUMOR THROMBUS; TUMOR VOLUME;

EID: 57049139008     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820802074449     Document Type: Article

References (35)

1. Parkin, DM, Bray, F., Ferlay, J. and Pisani, P. (2001) Mini review-Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, pp. 153-156.
2. Hong, SS, Kim, TK, Sung, KB, Kim, PN, Ha, HK Kim, AY et al. (2003) Extrahepatic spread of hepatocellular carcinoma: A pictorial review. Eur Radiol, 13, pp. 874-882.
3. Fan, ST, Lo, CM, Liu, CL, Lam, CM, Yuen, WK Yeung, C. et al. (1999) Hepatectomy for hepatocellular carcinoma: Towards zero hospital death. Ann Surg, 229, pp. 322-330.
4. El-Serag, HB and Mason, AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 340, pp. 745-750.
5. Margarit, C., Charco, R., Hidalgo, E., Allende, H., Castells, L. and Bilbao, I. (2002) Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg, 26, pp. 257-263.
6. Adam, R., Akpinar, E., Joann, M., Kunstlinger, F., Majno, P. and Bismuth, H. (1997) Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg, 225, pp. 39-49.
7. Chu, F. and Morris, DL (2006) Single centre experience of liver resection for hepatocellular carcinoma in patients outside transplant criteria. Eur J Surg Oncol, 32, pp. 568-572.
8. Yeh, CN, Lee, WC and Chen, MF (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: Two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol, 10, pp. 1070-1076.
9. Portolani, N., Coniglio, A., Ghidoni, S., Giovanelli, M., Benetti, A. Tiberio, GA et al. (2006) Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg, 243, pp. 229-235.
10. Poon, RT, Fan, ST, Ng, IO, Lo, CM, Liu, CL and Wong, J. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer, 89, pp. 500-507.
11. Shimada, M., Takenaka, K., Gion, T., Fujiwara, Y., Kajiyama, K. Maeda, T. et al. (1996) Prognosis of recurrence hepatocellular carcinoma: A 10-year surgical experience in Japan. Gastroenterology, 111, pp. 720-726.
12. Pandey, D., Lee, KH, Wai, CT, Wagholikar, G. and Tan, KC (2007) Long-term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg, 14, pp. 2817-2823.
13. Lau, WY, Leung, TW, Ho, SK, Chan, M., Machin, D. Lau, J. et al. (1999) Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet, 353, pp. 797-801.
14. Partensky, C., Sassolas, G., Henry, L., Paliard, P. and Maddern, GJ (2000) Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg, 135, pp. 1298-1300.
15. Boucher, E., Corbinais, S., Rolland, Y., Bourguet, P., Guyader, D. Boudjema, K. et al. (2003) Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology, 38, pp. 1237-1241.
16. Tabone, M., Vigano, L., Ferrero, A., Pellerito, R., Carbonatto, P. and Capussotti, L. (2006) Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol, 33, pp. 61-66.
17. Zhou, XD, Tang, ZY, Yu, YQ and Ma, ZC (1988) Clinical evaluation of cryosurgery in the treatment of primary liver cancer: Report of 60 cases. Cancer 61, pp. 1889-1892.
18. Zhou, XD and Tang, ZY (1998) Cryotherapy for primary liver cancer. Semin Surg Oncol, 14, pp. 171-174.
19. Chen, WT, Chau, GY, Lui, WY, Tsay, SH, King, KL Loong, CC et al. (2004) Recurrent hepatocellular carcinoma after hepatic resection: Prognostic factors and long-term outcome. Eur J Surg Oncol, 30, pp. 414-420.
20. Yang, Y., Nagano, H., Ota, H., Morimoto, O., Nakamura, M. Wada, H. et al. (2007) Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery, 151, pp. 196-202.
21. Llovet, J., Ricci, S., Mazzaffero, V., Hilgard, P., Raoul, J. Zeuzem, S. et al. (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol ASCO Annual Meeting Proceedings Part I, 25:18, p. A1.
22. Shah, SA, Cleary, SP, Wei, AC, Yang, I., Taylor, BR Hemming, AW et al. (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery, 141, pp. 330-339.
23. Tangkijnavnich, P., Anukulkarnkusol, N., Suwangool, P., Lertmaharit, S., Hanvivatvong, O. Kullavanijaya, P. et al. (2000) Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 31, pp. 302-308.
24. Farinati, F., Marino, D., Giorgio, M., Baldan, A., Cantarini, M. Cursaro, C. et al. (2006) Diagnostic and prognostic role of a-fetoprotein in hepatocellular carcinoma: Both or neither?. Am J Gastroenterol, 101, pp. 524-532.
25. Bodingbauer, M., Tamandl, D., Schmid, K., Plank, C., Schima, W. and Gruenberger, T. (2007) Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg, 94, pp. 1133-1138.
26. Takenaka, K., Yoshida, K., Nishizaki, T., Korenaga, D., Hiroshige, K. Ikeda, T. et al. (1995) Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg, 169, pp. 400-405.
27. Ono, T., Yamanoi, A., El-Assal, ON, Kohna, H. and Nagasue, N. (2001) Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: Metaanalysis of three randomized controlled trials. Cancer, 91, pp. 2378-2385.
28. Izumi, R., Shimizu, K., Iyobe, T., Ii, T, Yagi, M. Matsui, O. et al. (1994) Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology, 20, pp. 295-301.
29. Sasaki, A., Iwashita, Y., Shibata, K., Ohta, M., Kitano, S. and Mori, M. (2006) Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for respectable hepatocellular carcinoma. Eur J Surg Oncol, 32, pp. 773-779.
30. Muto, Y., Moriwaki, H., Ninomiya, M., Adachii, S., Saito, A. Takasaki, KT et al. (2008) Prevention of second primary tumours by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med, 334, pp. 1561-1567.
31. Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T. Yamamoto, J. et al. (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial. Lancet, 356, pp. 802-807.
32. Gautam, AM, Wilson, EA, Chen, PJ, Lee, PH, Lin, DY Wu, CC et al. (2007) A novel heparanase inhibitor, as adjuvant therapy for hepatocellular carcinoma: A large randomized phase II clinical trial. Proc AACR Ann Meet, 232, p. 2650.
33. Sun, HC, Tang, ZY, Wang, L., Qin, LX, Ma, ZC Ye, QH et al. (2006) Postoperative interferon a treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol, 132, pp. 458-465.
34. Ikeda, K., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y. Suzuki, F. et al. (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology, 32, pp. 228-232.
35. Lo, CM, Liu, CL, Chan, SC, Lam, CM, Poon, RT Ng, IO et al. (2007) A randomized, controlled trial of postoperative adjuvant interferion therapy after resection of hepatocellular carcinoma. Ann Surg, 245, pp. 831-842.